IL-33, a cytokine belonging to the IL-1 superfamily, along with its cognate receptor serum stimulation 2 (ST2) were reported to be upregulated in the liver of patients and mouse models of NASH (HFD, MCD) [107], and to be increased with the progression of the disease to hepatic fibrosis [108]. Here, IL1B is linked to metabolic dysfunction-associated steatohepatitis.